The low incidence of prostate cancer we found, coupled with the high proportion of clinically significant disease detected at biopsy, suggests that screening men with MSH2 and MSH6 pathogenic variants has a low risk of overdiagnosis of indolent cancers. This evidence concerns the gene MSH6 and prostate cancer.